This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cyanotech Announces 33% Expansion Of Astaxanthin Production Capacity

Responding to increased market demand for its natural Astaxanthin, Cyanotech Corporation (Nasdaq: CYAN) has announced a 33% expansion of Astaxanthin capacity at its production facility at Kona, Hawaii.

“With our Astaxanthin sales almost doubling since January, we have ramped up production and are realizing record yields month after month. In addition, we are adding 33% more Astaxanthin capacity, which should be fully on line in six months,” said Brent Bailey, President and CEO of Cyanotech. “We want to be sure we have capacity to fill the needs of all our customers in a timely manner, and be sure that all the consumers who want to try this exceptional nutrient can get it.”

Demand for Astaxanthin has increased steadily in the supplement industry this year since Dr. Joseph Mercola went on the Dr. Oz show, proclaiming it “The #1 Supplement you’ve never heard of that you should be taking.” This segment has aired three times and Dr. Mercola has followed up with several e-newsletters and YouTube segments extolling the benefits of Astaxanthin.

Mr. Bailey noted, “We’ve been able to benefit from this recognition because Cyanotech has the world’s largest production capacity and we had excellent inventory levels coming into this period of increased demand in January. We’re seeing demand continue to build nine months after the first Dr. Oz segment initially aired.”

Cyanotech’s Founder & Chief Scientific Officer, Gerald Cysewski, PhD, explained, “With our product, BioAstin Hawaiian Astaxanthin, people taking it for 2 to 6 weeks start to actually feel the benefits. This may mean decreased arthritis pain, improvements in skin quality, or maybe faster recovery from exercise and better workouts. Overall, about 80% of people will actually notice a difference within the first two months of use. So they continue to use it, and they tell their family & friends. This is why we see demand not only sustaining, but increasing.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.58 -1.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs